Background: Hypermethylation of tumor suppressor gene has been reported in various types of leukemia with potential involvement in the inactivation of regulatory cell cycle and apoptosis genes.
Introduction
Hypermethylation of DNA, which involves the addition of a methyl group to the carbon 5 position of the cytosine ring in a cytosine-guanine (CpG) pair, is known to be the most common and well-described epigenetic mechanism.
CpG pairs are usually underrepresented in most of the mammalian genome. However, short regions rich in CpG content known as CpG islands are found in the proximal promoter regions of almost half of the genes in the human genome, and are generally unmethylated in normal cells [1] [2] [3] . Methylation of these promoter-associated areas has been associated with gene silencing which serves as an alternative mechanism by inactivating functionally relevant genes related to diverse human pathologies including cancer and aging [4, 5] . In cancer, the aberrant hypermethylation of CpG islands surrounding gene promoter regions is the most well-investigated epigenetic change to occur in tumors.
CpG island hypermethylation has been described in various types of human malignancies, and is associated with inappropriate transcriptional silencing of functionally important cancer related genes, including tumor-suppressor genes [6, 7] .
Hypermethylation of promoter-associated CpG islands also has been found in acute lymphoblastic leukemia (ALL).
Initial studies in ALL were targeted on the analysis of single genes such as calcitonin [8] [9] [10] , p73 [11, 12] , p15 [13] [14] [15] , E-cadherin (CDH1) [16] , and so on. Further studies focusing upon hypermethylation of multiple genes have proved that concurrent methylation of multiple genes is a common feature in both adult and childhood ALL [17, 18] . The studies in Philadelphia chromosome (Ph)-negative adult ALL and acute myeloid leukemia (AML) have shown that residual methylation at remission could predict poor prognosis, suggesting that DNA methylation could be a potential biomarker in ALL [19, 20] . Furthermore, many studies implicated that methylation pattern in childhood ALL patients at diagnosis were different from that of adults [21] [22] [23] [24] . To study these issues, we examined methylation status of three key genes in leukemia, CDH1, p16 and DAPK, at the time of initial diagnosis and at the time of morphologic complete remission (CR). CDH1 is a member of membrane glycoprotein, its function as a tumor suppressor and its loss due to methylation enables disaggregation of cancer cells from one another and increases their metastatic potential. p16 is a important member of cyclin dependent kinase inhibitor, regulated by a feedback loop with Rb. DAPK is a Ca +2 /Calmodulin regulated serine/threonine kinase, associated with the cytoskeleton, and participates in a wide range of apoptotic pathways.
We also aimed to investigate the correlation of methylation status with clinicopathological features.
Materials and Methods

1) Patients and samples
We studied 43 patients (24 
2) Methylation specific PCR (MSP)
To study methylation patterns at the time of initial diagnosis and CR in childhood ALL, we analyzed the methylation status of three key genes related to its pathogenesis, CDH1, p16 and DAPK, in 43 patients. Gene selection was based on the previous methylation studies in ALL [17, 21, 27, 28] ; we selected the three genes that are known to be frequently methylated in childhood ALL [18, 29] .
Mononuclear cells were isolated using Ficoll-Hypaque density gradient centrifugation, and genomic DNA was extracted with QIAmp DNA blood mini kit (QIAGEN, CA, USA) following procedures according to the manufacturer's instructions. Genomic DNA was modified using the sodium bisulfate as previously described by Herman et al. [30] . One 
3) Statistical analysis
For statistical purposes, patients were classified into two different groups: unmethylated (no methylated genes) and methylated (at least one methylated gene). Association of methylation status with patient characteristics were analyzed using   test or Fisher exact test. Overall survival (OS) was measured from the day of diagnosis until death from any cause and was censored only for patients known to be alive at last contact. Disease-free survival (DFS) was measured from the day that CR was established until either relapse or death without relapse, and it was censored only for patients who were alive without evidence of relapse at the last follow-up. Comparisons among the groups were performed by analysis of variance with SPSS ver. 12.0 for Windows (SPSS Inc., Chicago, IL, USA). Estimated 5-year disease free survival and overall survival were based on the Kaplan-Meier method, and differences were tested using the log-rank test. An effect was considered statistically significant if the P-value was 0.05 or less.
Results
1) Methylation pattern at initial diagnosis and CR
Among 43 patients, methylation frequency of each gene at the time of initial presentation was as follows: 60.4%
(n=26) for CDH1, 4.6% (n=2) for p16, and 13.9% (n=6) for DAPK. 67.4% (n=29) of all patients had methylation of at least one gene, whereas 32.6% (n=14) of the patients had no methylation at all. Five (11.6%) patients had methylation of two genes. Methylation of CDH1 showed considerably high frequency of methylation as previously reported [18] .
However, p16 and DAPK were rarely methylated in this study.
To 
2) Clinical characteristics and methylation profile
We studied the association between DNA methylation 
P=0
.03 (differences were tested using the log-rank test).
status and clinicopathological characteristics, including age, gender, initial WBC count, pretreatment cytogenetic analysis and NCI risk group. Methylation profiles of the patients at initial presentation according to various clinicopathological characteristics are summarized in Table 1 .
Methylation of CDH1 was observed in 62.5% (15/24) of the male patients and 57.9% (11/19) of the female patients.
By age, methylation of CDH1 was shown in 25.0% (1/4) of patients younger than two years of age, 58.0% (18/31) of patients between two and 10 years, and 87.5% (7/8) of patients older than 10 years.
Methylation of CDH1 gene was also found in 62.5% (20/32) of patients whose initial WBC counts were less than 50,000/μL and in 54.5% (6/11) of those with more than 50,000/μL of WBCs. The same gene was methylated in Estimated 5-year OS of all patients was 80.4% for standard risk patients and 65.6% for those with high risk.
Estimated 5-year OS for methylated patients was 77.3% and 83.2% for nonmethylated ones. Five year DFS for methylated patients was 75.5% and 81.8% for the nonmethylated group. There was no statistical significance for OS and DFS between methylated and nonmethylated patients.
Discussion
There has been much evidence that DNA methylation plays a key role in cancer development [6, 31] . An explosive amount of data has indicated the importance of epigenetic processes, especially those resulting in the silencing of key regulatory genes in all stages of cancer development [32] .
In ALL, study of epigenetic alterations was a relatively obscure field of research before; however, it has shown a considerable progress in the last decade. Studies on methylation of multiple genes in both adults and child patients have shown that multiple promoter CpG islands are common features in both groups [17, 18, 29, 33] . However, difference in the patterns of methylation between pediatric and adult ALL has been suggested in several studies. While the report of Garcia-Manero et al. [33] indicated that there were no obvious differences in terms of the frequency of methylation observed in childhood and adult ALL, another study showed that epigenetic inactivation of p73/p15/p57 which was observed in close to 25% of adult patients was extremely rare in the younger patients [21] . Nakamura et al. [22] reported that methylation of p16, a rare event in primary ALL [27, 34] , has been shown to be present in pediatric cases with MLL alterations. Methylation of FHIT gene showed a similar pattern [23, 24] . Even though the above results need to be confirmed in other larger group of patients, they suggest that prognostic differences between the age groups could be related in part to different methylation patterns [35] .
Several studies have focused on whether DNA methylation could be used as a marker of residual disease. One study of methylation profiles of five genes (ER, MDR1, p73, p15 and p16) in a group of patients before therapy and at the time of morphologic relapse showed that a gain of methylation may have a role in relapse/resistance mechanisms in adult ALL, which can suggest a potential role of DNA methylation profile in implicating relapse and resistance [4] . Another study conducted in adult Ph chromosome-negative ALL patients showed that 28% of patients had detectable residual methylation at remission, and the presence of residual p73 methylation was associated with a significant shorter duration of first CR and OS [19] . As many authors suggested the different characteristics of methylation between adult and pediatric patients, methylation pattern at remission status in childhood ALL can differ from those of adults.
In this study, we have analyzed the methylation patterns of CDH1, p16 and DAPK genes at the time of initial diagnosis and at the time of CR in 43 childhood ALL. Aberrant DNA methylation was most frequently observed in CDH1 gene (60.4%), while it was rare in p16 and DPAK gene had several such cases. As Gutierrez et al. [18] reported high frequency (72%) of CDH1 methylation in childhood ALL, this data supports this result. Age was the only factor which showed statistically significant association with the presence of DNA methylation of the studied genes (P=0.03). Even though patients under age of two years are known to have poor prognosis, a majority of patients did not show any methylation. Most patients over 10 years had methylation.
This result can be supported by the concept that methylation increases with aging [36] , and may suggest a role of more significant mechanism in leukemogenesis other than epigenetic mechanism in those young children under age of two. However, since this study included only a very small number of genes among many different cancer-related genes in limited number of patient, further survey is definitely required. we did not undergo quantitative studies, the analysis according to the level of methylation was unavailable. We believe that further qualitative analysis is certainly needed.
Next, the follow up period was relatively short to evaluate the significance of methylation on survival outcome. Further studies of a larger patient number with the more selected genes and a long term follow up will give us better understanding of the driving mechanisms and also therapeutic interventions for childhood ALL at diagnosis, treatment and relapse.
In conclusion, we have analyzed methylation status of CDH1, p16 and DAPK genes in childhood ALL at the time of initial diagnosis and at CR using MSP method. Methylation of CDH1 was frequently detected, showing significant association with age. Since all of the DNA methylation presented at the time of diagnosis revealed total unmethylation at CR and all healthy individuals showed complete unmethylation. Further studies with larger populations and more relevant genes should be conducted in methods that include quantitative ones.
